It is the third rail of Twitter, Maintenance of Certification. But ASN wanted to tackle this head on with a public position and Twitter chat. Take a look at the analytics, storify and transcript.
This week, we will discuss the use of renal autologous cell therapy (REACT) in diabetic kidney disease.
This week, we will discuss 2026 KDIGO anemia management in patients with kidney disease
This week, we aim for an INFINITe allograft lifespan. or flozination in kidney transplant.
This week, we will discuss the POTCAST trial. It is a cardiology trial - but potassium belongs to nephrology.
It is the third rail of Twitter, Maintenance of Certification. But ASN wanted to tackle this head on with a public position and Twitter chat. Take a look at the analytics, storify and transcript.